Terms: = Breast cancer AND BTK, AGMX1, 695, ENSG00000010671, XLA, IMD1, RP1-164F3_2, MGC126262, BPK, ATK, MGC126261, Q06187, AT, PSCTK1 AND Clinical Outcome
1479 results:
1. Immunohistochemical Expression and Prognostic Value of COX-2 and Alpha-Smooth Muscle Actin-positive cancer-associated Fibroblasts in Feline Mammary cancer.
Guimarães JCM; Petrucci G; Prada J; Pires I; Queiroga FL
In Vivo; 2024; 38(2):598-605. PubMed ID: 38418156
[TBL] [Abstract] [Full Text] [Related]
2. Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A; Khan U; Rathod H; Jain K; Dwivedi A; Rajesh A
J Cancer Res Ther; 2023 Oct; 19(7):1697-1713. PubMed ID: 38376268
[TBL] [Abstract] [Full Text] [Related]
3. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.
Cisneros-Villanueva M; Fonseca-Montaño MA; Ríos-Romero M; López-Camarillo C; Jiménez-Morales S; Langley E; Rosette-Rueda AS; Cedro-Tanda A; Hernández-Sotelo D; Hidalgo-Miranda A
Sci Rep; 2024 Jan; 14(1):1483. PubMed ID: 38233470
[TBL] [Abstract] [Full Text] [Related]
5. Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
Hardy-Abeloos C; Xiao J; Oh C; Barbee D; Shah B; Maisonet O; Perez C; Adams S; Schnabel F; Axelrod D; Guth A; Karp N; Cahlon O; Gerber N
Breast Cancer Res Treat; 2024 Apr; 204(3):485-495. PubMed ID: 38183516
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative breast cancer.
Coakley M; Villacampa G; Sritharan P; Swift C; Dunne K; Kilburn L; Goddard K; Pipinikas C; Rojas P; Emmett W; Hall P; Harper-Wynne C; Hickish T; Macpherson I; Okines A; Wardley A; Wheatley D; Waters S; Palmieri C; Winter M; Cutts RJ; Garcia-Murillas I; Bliss J; Turner NC
Clin Cancer Res; 2024 Feb; 30(4):895-903. PubMed ID: 38078899
[TBL] [Abstract] [Full Text] [Related]
7. Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients.
Zwager MC; Holt-Kedde I; Timmer-Bosscha H; de Bock GH; Werker PMN; Schröder CP; van der Vegt B; Arjaans M
Breast Cancer Res Treat; 2024 Feb; 204(1):27-37. PubMed ID: 38057686
[TBL] [Abstract] [Full Text] [Related]
8. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
9. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
10. TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification.
Chaojun L; Pengping L; Yanjun L; Fangyuan Z; Yaning H; Yingbo S; Qi C; Hui L
Aging (Albany NY); 2023 Nov; 15(22):12890-12906. PubMed ID: 37950731
[TBL] [Abstract] [Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients.
Milovanović J; Vujasinović T; Todorović-Raković N; Greenman J; Hranisavljević J; Radulovic M
Pathol Res Pract; 2023 Dec; 252():154923. PubMed ID: 37948997
[TBL] [Abstract] [Full Text] [Related]
12. Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study.
Fadem SJ; Crabtree BF; O'Malley DM; Mikesell L; Ferrante JM; Toppmeyer DL; Ohman-Strickland PA; Hemler JR; Howard J; Bator A; April-Sanders A; Kurtzman R; Hudson SV
BMC Prim Care; 2023 Nov; 24(1):235. PubMed ID: 37946132
[TBL] [Abstract] [Full Text] [Related]
13. Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study.
Gozalishvilli-Boncheva A; Gonzalez-Espinoza IR; Castro-Ponce A; Bravo-Gutiérrez OA; Juárez-Salazar G; Montes-de-Oca-Moreda RI; Aguirre-Flores E; Coyotl-Huexotl M; Orozco-Luis J; Chiquillo-Domínguez M; Garibay-Díaz JC; Aranda-Claussen JE; Ponce-de-León EA; Sánchez-Sosa S; Sabaté-Fernández M; García-Reyna JC; Cordero-Vargas C; González-Blanco MJ; Aguilar-Priego JM; Sánchez-Fernández NJ; Cortés-García CA; González-Lozada LE; Miguel-Cruz E; Ceja-Utrera FJ; Hernández-Garcia MS; Piña-Vazquez M; Aguilar-Jiménez C
Breast Dis; 2023; 42(1):305-313. PubMed ID: 37807773
[TBL] [Abstract] [Full Text] [Related]
14. clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract] [Full Text] [Related]
15. GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model.
Hernández-Aceves JA; Cervantes-Torres J; Torres-García D; Zuñiga-Flores FJ; Patiño-Chávez OJ; Peña Agudelo JA; Aguayo-Flores JE; Garfias Y; Montero-León L; Romero-Romero L; Pérez-Torres A; Fragoso G; Sciutto E
Cancer Immunol Immunother; 2023 Nov; 72(11):3825-3838. PubMed ID: 37736849
[TBL] [Abstract] [Full Text] [Related]
16. Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival.
Antonini M; Mattar A; Bauk Richter FG; Pannain GD; Teixeira MD; Amorim AG; Ferraro O; Guedes Lopes RC; Gebrim LH; Real JM
Breast; 2023 Dec; 72():103577. PubMed ID: 37722319
[TBL] [Abstract] [Full Text] [Related]
17. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant breast cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract] [Full Text] [Related]
18. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
[TBL] [Abstract] [Full Text] [Related]
19. Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate cancer.
Neeb A; Figueiredo I; Gurel B; Nava Rodrigues D; Rekowski J; Riisnaes R; Ferreira A; Miranda S; Crespo M; Westaby D; de Los Dolores Fenor de La Maza M; Guo C; Carmichael J; Grochot R; Tunariu N; Cato ACB; Plymate SR; de Bono JS; Sharp A
Lab Invest; 2023 Nov; 103(11):100245. PubMed ID: 37652207
[TBL] [Abstract] [Full Text] [Related]
20. clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study.
Yang L; Lin H; Shen Y; Roy M; Albarracin C; Ding Q; Huo L; Chen H; Wei B; Bu H; Bedrosian I; Wu Y
Breast Cancer Res Treat; 2023 Nov; 202(1):23-32. PubMed ID: 37566192
[TBL] [Abstract] [Full Text] [Related]
[Next]
